Trials / Completed
CompletedNCT05765890
Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 675 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to better understand the main barriers to earlier diagnosis and better management of MASLD/MASH patients and to understand the key barriers to adoption of guidelines. This study is a cross-sectional design, conducted across 5 countries in Europe- France, Germany, Spain, United Kingdom (UK), Italy. Study participants, Hepatologists and other metabolically focused healthcare providers (HCPs), will be recruited to complete a 15 minute self-administered online survey.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No treatment given | No treatment given |
Timeline
- Start date
- 2023-03-24
- Primary completion
- 2023-09-12
- Completion
- 2023-09-12
- First posted
- 2023-03-13
- Last updated
- 2023-10-11
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT05765890. Inclusion in this directory is not an endorsement.